Download our free ebook: your guide to CRPS filled with incredible knowledge on the condition

CRPS Treatment: pain in ankle for 10 months

General details and patient's info

Gender:Male.
Age:44 years old at the time of treatment.
Home Country:United States of America,
Illness duration:10 months prior to the Neridronate Treatment.
Cause:Left ankle facture, biking accident.
Symptoms:Very cold sensation through foot and ankle associated with burning in toes. Electric shocks throughout the foot. The first toe has become arthritic. Flexion of the ankle very limited.
Clinical evaluation:CRPS diagnosis after a bimalleolar ankle facture and syndesmotic disruption. It was surgically corrected with open reduction and internal fixation.
Time of treatment:May 2019.

Why the Patient decided to undergo the CRPS Treatment in Italy

The patient was searching online for treatments and discovered the Neridronate treatment. He studied cases throughout our website and contacted us quickly.

Medical treatment the Patient underwent in Italy

Complex regional pain syndrome (CRPS) is a severely painful and disabling disease for which a multitude of therapeutic interventions have been proposed. In the past two decades, only Bisphosphonates gained credibility. In recent years, more convincing evidence has become available on the use of Parenteral Neridronate. Since 2014, this drug is registered and marketed in Italy for the treatment of CRPS. To date, the only therapeutic schedule that is recognized to be able to confer benefit is the intravenous (IV) administration of 100 mg given 4 times.

4 neridronate infusions (100mg, I.v. in saline Solution 0,9% 250 ml)
See the Official Study on the Oxford Academics website: https://academic.oup.com/rheumatology/article/52/3/534/1777330
4 Pantoprazole infusions; Paracetamol.

Daily Report

DAY 1: Arrival at the Venice airport, greeted by his Patient Manager, followed by check-in at his Hotel in Vicenza. Briefing focused on next days.

DAY 2: Rest day, in contact with Patient Manager.

DAY 3: Morning pick-up by his Patient Manager, 1st visit with the Rheumatologist Professor, 1st Neridronate infusion.

DAY 4: Morning pick-up by his Patient Manager, 2nd Neridronate infusion, then touring of Verona. The patient has some flu like symptoms.

DAY 5: Morning pick-up by his Patient Manager and 3rd Neridronate infusion. The patient still has some flu like symptoms.

DAY 6: Morning pick-up by his Patient Manager, 2nd visit with the Rheumatologist Professor and last Neridronate infusion. The patient feels better today.

DAY 7: Morning pick-up by his Patient Manager, and day trip to Soave.

DAY 8: Morning pick-up by his Patient Manager and visit of Marostica and Bassano del Grappa.

DAY 9: Morning pick-up by his Patient Manager and day trip to Venice.

DAY 10: Morning meeting with Patient Manager and rest day.

DAY 11: Morning pick-up by his Patient Manager and drop-off at Venice airport.

Follow up

AUGUST 2019 (3 months after Neridronate treatment): the patient feels better and says he only has pain when he walks.

JULY 2023 (4 years after Neridronate treatment): the patient says his CRPS has been much better since the Neridronate treatment. He finds that alcohol and refined foods may set it off but nowhere near it used to be. He also had a further surgery without flare.

Conclusion

Even though he could not reach full remission, the patient reported very good results and improvements of his condition. After 4 years, he still feels much better and learnt how to manage some symptoms that he still may experience so that he can easily perform his daily activities.

DISCLAIMER
This is not a medical case study; it merely describes each patient’s journey, and it omits all personal data. The people who redacted it are not doctors but all the facts reported are objective and represent the patient’s reality thanks to the information in our possession. The report is not part of any clinical trials. It was written to provide more information to patients who have made multiple requests for treatment outcomes of cases like theirs.